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Abstract
Epilepsy is misdiagnosed in up to 25% of patients, leading to serious and long-lasting conse-
quences. Recently, circulating microRNAs have emerged as potential biomarkers in a num-
ber of clinical scenarios. The purpose of this study was to identify and to validate circulating
microRNAs that could be used as biomarkers in the diagnosis of epilepsy. Quantitative
real-time PCR was used to measure plasma levels of three candidate microRNAs in two
phases of study: an initial discovery phase with 14 patients with mesial temporal lobe epi-
lepsy (MTLE), 13 with focal cortical dysplasia (FCD) and 16 controls; and a validation cohort
constituted of an independent cohort of 65 patients with MTLE and 83 controls. We found
hsa-miR-134 downregulated in patients with MTLE (p = 0.018) but not in patients with FCD,
when compared to controls. Furthermore, hsa-miR-134 expression could be used to dis-
criminate MTLE patients with an area under the curve (AUC) of 0.75. To further assess the
robustness of hsa-miR-134 as a biomarker for MTLE, we studied an independent cohort of
65 patients with MTLE, 27 of whom MTLE patients were responsive to pharmacotherapy,
and 38 patients were pharmacoresistant and 83 controls. We confirmed that hsa-miR-134
was significantly downregulated in the plasma of patients with MTLE when compared with
controls (p < 0.001). In addition, hsa-miR-134 identified patients with MTLE regardless of
their response to pharmacotherapy or the presence of MRI signs of hippocampal sclerosis.
We revealed that decreased expression of hsa-miR-134 could be a potential non-invasive
biomarker to support the diagnosis of patients with MTLE.
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Introduction
The diagnosis of epilepsy is currently based on neurological history, EEG and neuro-imaging
findings [1]. Although with very well defined parameters it may still present a challenge in
more complex patients since it also requires a certain degree of clinical experience for the
interpretation of the findings in the context of single patients [2]. The correct diagnosis of epi-
lepsy would allow patients to receive an appropriate treatment and could prevent unnecessary
side effects from long-term medication such as adverse psychological and social consequences.
However, misdiagnosis of epilepsy is frequent, occurring in around 25% of patients [3] and in
paediatric series this number is higher; 39% of children in Denmark do not receive correct
diagnosis [4]. Furthermore, the estimated cost of wrong diagnoses of epilepsy could reach
more than £100,000,000 per year in England [5]. Therefore, there is still the need for additional
biomarkers which could improve and support the diagnosis of epilepsy [6, 7], and for better
defining cohorts for clinical trials.
Circulating microRNAs are emerging as candidates for use as biomarkers in a number of
disorders, ranging from cancer (e.g., miR-21 in breast cancer) [8] to coronary artery disorders
(e.g., miR-155) [9]. These are small non-coding RNA molecules (~20 nucleotides) present in
extracellular human body fluids, including plasma or serum. Currently, it is well known that
induced changes of microRNAs levels are stable in plasma and can be strongly associated with
specific disease states [10]. Moreover, circulating microRNA measurement is a non-invasive
and easily quantifiable procedure [11].
To our knowledge there are only four reports investigating serum levels of microRNAs in
patients with epilepsy as compared to healthy controls [12–15]. Given the great heterogeneity
of epilepsy syndromes it becomes clear that additional studies are urgently needed.
In this context, the main goal of this study is to identify and validate a robust and non-inva-
sive biomarker to assist in the diagnosis of epilepsy. We quantified plasma levels of three candi-
date microRNAs, previously associated with epilepsy: hsa-miR-134 [16] reported in temporal
lobe epilepsy (TLE); hsa-miR-31 [17], identified by our group in brain tissue from patients
with FCD, and hsa-miR-23a [18] identified in rat models of TLE.
Materials and methods
Patients and study design
We recruited patients from 2013 to 2015 at the outpatient epilepsy clinic of the University of
Campinas (UNICAMP) hospital, which is a tertiary centre for epilepsy care. Prior to undergo
any study procedures all patients and control subjects signed a written informed consent. The
Comitê de E´tica em Pesquisa from the University of Campinas specifically approved this study
(CAAE: 12112913.30000.5404).
The clinical evaluation of patients was performed by neurologists with experience in the
treatment of patients with epilepsy. All patients were interviewed using a structured question-
naire gathering information regarding age, onset of epilepsy (OSF), history of febrile seizure
(FS), family history of epilepsy (FH) and number of AEDs used. In addition, all patients under-
went a neurological exam, serial interictal EEGs and high resolution MRI with a specific epi-
lepsy protocol. Hippocampal atrophy and other MRI signs of hippocampal sclerosis (HS) were
assessed by visual analyses and the images were classified as having normal findings or signs of
HS. Patients with dual pathology or tumours were not included. Clinical characteristics are
summarised in Table 1. Controls individuals were Brazilian unrelated individuals, with no
neurological or psychiatric disease, who voluntarily agreed to donate plasma samples to our
study.
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The study was performed in two phases: an initial discovery phase and a subsequent valida-
tion phase. First, we enrolled 14 patients with MTLE classified according to clinical, electroen-
cephalographic and MRI criteria [19]; 13 patients with focal cortical dysplasia (FCD) type II
confirmed by histopathology [20] as well as 16 healthy control subjects, without epilepsy.
Subsequently, in a validation phase, we enrolled an additional independent cohort of 65
patients with MTLE using the same diagnostic criteria as described above. These patients were
subsequently divided in two groups according to their response to AED treatment and seizure
frequency: i) drug-responsive MTLE (n = 27), defined as seizure freedom for at least 24
months and ii) drug-resistant MTLE (n = 38), defined as any frequency of seizures in the last
24 months, after the trial of at least two AEDs at optimal doses. We also recruited an additional
83 healthy individuals without epilepsy as a control group.
Table 1. Clinical findings in patients with FCD, MTLE and control individuals enrolled in both phases of the study.
Discovery cohort
Variable FCDType II(n = 13) MTLE(n = 14) Controls(n = 16) p-value
Sex Male 10 6 6 0.104
Female 3 8 10
OSF Yes 12 6 - 0.100
No 1 8 -
HS Yes 0 14 - 1.504e-06
No 13 0 -
FS Yes 2 3 - 1
No 11 11 -
FH Yes 5 7 - 0.83
No 8 7 -
Average number of AEDs
used
5.8 4.15 - 0.60
Seizure frequency (monthly)
*
157 12.1 - 2.2e-16
Validation cohort
MTLE AED Responsive(n = 27) MTLE AED Resistant (n = 38) Controls (n = 83) p-value
Sex Male 12 16 35 1
Female 15 22 48
OSF Yes 11 14 - 0.952
No 16 24 -
HS Yes 16 32 - 0.049
No 11 6 -
FS Yes 6 9 - 1
No 21 29 -
FH Yes 12 14 - 0.72
No 15 24 -
Average number of AEDs
used
2.53 4.97 - 0.37
Seizure frequency (monthly)
*
0 6.35 - 0.012
FCD: Focal Cortical Dysplasia; MTLE: Mesial Temporal Lobe Epilepsy AED: antiepileptic drug; OSF: Onset of seizures in the1st decade of life; HS: MRI
sings of hippocampal sclerosis; FS: Antecedent of febrile seizure; FH: Presence of family history of epilepsy. χ2 test, Yates correction, p<0.05.
* Complex focal seizures and generalized tonic-clonic seizure
https://doi.org/10.1371/journal.pone.0173060.t001
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Blood collection and RNA isolation
For plasma preparation, we collected peripheral blood (4 ml) into EDTA tubes held on ice for
up to three hours. The tubes were subjected to centrifugation at 515 x g for 10 min, 4˚C. Next,
1 ml aliquots of the plasma were transferred to 1.5 ml tubes and centrifuged at 12,000 x g for
10 min, 4˚C to pellet any remaining cellular debris. Subsequently, the supernatant was trans-
ferred to fresh tubes and stored at -80˚C. The concentration of free haemoglobin was mea-
sured in patient plasma by spectrophotometric (BioTek Instruments, Inc., Winooski, EUA)
method and samples with A414 reading > 0.2 were excluded. MirVana PARIS microRNA Iso-
lation kit was used for extraction of the enriched fraction of small RNAs according to the man-
ufacturer instructions (Ambion Inc, Austin, USA). The final elution volume was 35ul RNase-
free water. The concentration and purity were analysed using spectrophotometer.
Reverse transcription and quantitative real-time PCR
A fixed volume of 5 ul of small RNA-enriched fraction was used as an input into a reverse
transcription (RT) reaction using TaqMan™ reverse transcription kit (Life Technologies, Fos-
ter City, USA) with microRNA specific stem-loop primers, following the manufacturer
instructions. The primers used were: hsa-miR-23a (ID399), hsa-miR-31 (MIMAT0000089,
ID 2279) and hsa-miR-134 (MIMAT0000447, ID 1186) as candidate microRNAs; hsa-miR-
16 (MIMAT0000069, ID391), hsa-miR-191(MIMAT0000440, ID 2299), hsa-miR-451
(MIMAT0001631, ID 1141), RNU24 (ID 1001), and RNU48 (ID1006) as endogenous con-
trols (Life Technologies). We selected hsa-miR-191and hsa-miR-451 for endogenous con-
trols as both are expressed at high levels in plasma and they were relatively stable across
samples from patients and control individuals. Data was analyzed with the DataAssist™ Soft-
ware (Life Technologies). The threshold cycle (Cq) values were determined using automatic
baseline settings. All reactions were performed in triplicate. The relative quantification was
calculated with 2-ΔΔCt method after normalization to hsa-miR-191 and hsa-miR-451. Micro-
RNAs with an expression level lower than the threshold value (Cq36) and with a detection
rate below 75% in both group samples were considered rejected. MicroRNA expression levels
(row data) as well clinical information of patients included in this study are available in the
supporting material; this data is part of our relevant minimal data set (S1 Table).
Statistical analysis
We used the R statistical environment (version 3.1.2 (2014-10-31) [21] for statistical analysis.
Since microRNA expression levels did not follow a normal distribution, we performed a loga-
rithmic transformation. The level of significance, alpha, was set to 0.05 for log2 transforms
of relative expression (RQ), which corresponds to 2-ΔΔCt Bonferroni-adjusted p-values. We
used two-sample t-tests to perform comparisons of log2 (RQ) between the available groups for
each of the three microRNAs. The comparisons of interest were: in the discovery phase, FCD
versus controls, MTLE versus controls and FCD versus MTLE; in the validation phase, MTLE
versus controls, AED-responsive versus controls, AED-resistant versus controls, and AED-
responsive versus AED-resistant patients.
Sensitivity, specificity and area under the curve (AUC) for specific microRNAs were esti-
mated using receiver operator characteristic (ROC) using the caret R package [22]. We applied
the bootstrap resampling strategy to optimize the AUC via the caret package implementation.
Different clinical parameters between the groups of patients and controls were compared
using chi-squared test with Yates correction.
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Results
First, we aimed to determine if differences in microRNA levels are present in patients with
epilepsy independent of aetiology. We identified that only hsa-miR-134 was significantly
downregulated in plasma of patients with MTLE when compared to controls (p = 0.018; Fig
1A). In addition, plasma levels of this microRNA could discriminate patients with MTLE from
control individuals with an AUC of 0.75 with sensitivity of 65% and specificity of 75% in
plasma (Fig 1B; 95%CI: 0.589–0.911). However, no difference in plasma levels of hsa-miR-134
was observed in patients with FCD compared to controls (p = 1; Fig 1A; AUC = 0.45). More-
over, expression values of hsa-miR-23a (p MTLE x Control = 1; p FCD X Control = 0.356; p MTLE X
FCD = 0.266; Fig 1C) and hsa-miR-31 (p MTLE x Control = 1; p FCD X Control = 1; p MTLE X FCD =
0.88; Fig 1D) were not different among the groups analysed.
Based on these initial results, we decide to focus on hsa-miR-134 in further analyses aiming
to verify whether hsa-miR-134 was robust enough to identify patients with MTLE independent
Fig 1. Plasma levels of the three candidates microRNAs quantified in the first cohort of patients (discovery phase). Box plot depicting the log2
transformed relative expression (RQ) of (A) hsa-miR-134 in the three groups, 14 patients with MTLE, 13 patients with FCD and 16 control individuals
without epilepsy; (B) receiver-operator curve (ROC) of hsa-miR-134 comparing controls and patients with MTLE. (C) Box plot depicting the log2
transformed RQ values of hsa-miR-23a and (D) hsa-miR-31 in the same three groups. Expression levels were normalized to hsa-miR-191 and hsa-miR-
451. The only comparison with statistically significant difference, determined by Student t-test corrected by Bonferroni, is marked with a star (*). Circles
indicate outliers.
https://doi.org/10.1371/journal.pone.0173060.g001
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of specific clinical characteristics, including response to treatment with AEDs. Therefore, we
quantified levels of hsa-miR-134 in the plasma of an additional independent cohort of 65
patients with MTLE. We confirmed that hsa-miR-134 was significantly downregulated in the
plasma of these patients when compared with controls without epilepsy (p = 0.00033; Fig 2A).
Furthermore, the accuracy for identifying patients with MTLE was AUC = 0.671 with a sensi-
tivity of 75% and a specificity of 58% (Fig 2B; 95%CI: 0.580–0.755). We also showed that hsa-
miR-134 is downregulated both in patients with AED-responsive MTLE (p = 0.0026; Fig 2C)
and AED-resistant MTLE (p = 0.044; Fig 2C), when compared to control subjects. No differ-
ence in hsa-miR-134 plasma levels was observed between AED-responsive and AED-resistant
MTLE patients (p = 0.88; Fig 2C). Subsequently, we also evaluated whether signs of HS on
MRI could have an impact on hsa-miR-134 plasma levels in patients with MTLE and found
no statistical difference between these two groups of (p = 0.8522; Fig 2D). Finally, we investi-
gate if seizure-frequency could affect hsa-miR-134 expression and we used a score of up to one
Fig 2. Plasma levels and ROC plot calculated for hsa-miR-134 in the validation cohort. (A) Box-plots depicting log2 transformed RQ values of hsa-
miR-134 plasma levels comparing 65 patients with MTLE with 83 control subjects without epilepsy; (B) ROC curve of data shown in (A). (C) Box-plots
depicting log2 transformed RQ values of hsa-miR-134 plasma levels comparing 27 patients with AED-responsive MTLE, 83 control subjects and 38
patients with AED-resistant MTLE. (D) Box-plots depicting log2 transformed RQ values of hsa-miR-134 plasma levels comparing patients with MTLE with
(n = 48) and without (n = 17) the presence of signs indicating HS on MRI. Expression levels were normalized to hsa-miR-191 and hsa-miR-451.
Comparisons with statistically significant differences, determined by the Student t-test corrected by Bonferroni, are marked with stars (*).
https://doi.org/10.1371/journal.pone.0173060.g002
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seizure per month to define two groups of patients according to seizure frequency [14] and
found no statistical difference between the two groups (p = 0.633; data not shown) regarding
plasma levels of hsa-miR-134 plasma.
Discussion
We investigated plasma levels of three microRNAs in a study designed to identify a non-inva-
sive biomarker that could assist in the sub-syndromic diagnosis of epilepsy. We selected
microRNAs hsa-miR-134, hsa-miR-31 and hsa-miR-23a, since they have been reported in
abnormal levels in tissue of patients or animal models with different types of epilepsy [16–18].
Our results clearly show a significant downregulation of hsa-miR-134 in plasma of patients
with MTLE. In addition, we demonstrated reduced levels of hsa-miR-134 in two independent
cohorts of patients with MTLE, regardless their response to treatment with AEDs and presence
of MRI signs of HS. The fact that we found no difference in hsa-miR-134 plasma levels
between AED-responsive and AED-resistant MTLE patients indicates that hsa-miR-134
plasma levels is not influenced by response to treatment and it is therefore, a biomarker for
MTLE and not for response to AED treatment. We found no difference in the levels of any of
the microRNAs tested in patients with FCD compared to controls.
Jimenez—Mateos and collaborators [16], in their elegant study, were the first to show that
miR-134 is upregulated in both temporal lobe and hippocampal pyramidal neurons of phar-
macoresistant patients with TLE. They suggested that dysregulation of this microRNA could
be a response to abnormal neuronal activity, potentially associated with alterations in dendritic
spines density. Here we show, for the first time, that hsa-miR-134 is present in plasma of
patients with MTLE and it is downregulated in comparison to healthy controls, suggesting
that hsa-miR-134 could be used as a biomarker for MTLE. Similarly, Takana et al. [23]
revealed that plasma miR-92a was found downregulated in non-Hodgkin’s lymphoma com-
pared with healthy subjects, although miR-92a is overexpressed in malignant lymphoma cells.
They suggested that microRNAs are packaged inside exosomes that are secreted from cells, but
in tumour these exosomes may be encompassed by cancer cells and consequently miR-92a
decreases from the blood.
Because 15–38% of patients with MTLE have normal MRI [24, 25], this group of patients
may constitute an additional challenge for diagnosis [26]. Thus, the identification of a non-
invasive biomarker that could be used to support the diagnosis of MTLE in these patients
would be of paramount importance. Our results show that hsa-miR-134 could also be used to
support diagnosis of MTLE in patients without MRI signs of HS. Thus, plasma levels of hsa-
miR-134 could be used, in addition to other clinical and EEG parameters to help distinguish-
ing between psychogenic non-epileptic seizures (PNES) and epileptic seizures. PNES diagno-
sis, particularly in individuals with normal MRI, may be lengthy, due to the difficulty and the
challenge to establish the correct diagnosis [27, 28] and therefore, patients with PNES could
significantly benefit from the use of a minimally invasive biomarker of epileptic seizures. Nev-
ertheless, since we did not directly performed this type of analysis, further studies including
patients with PNES should be performed to further explore the usefulness of determining
plasma levels of hsa-miR-134 in this specific clinical application.
To date, few studies have addressed the issue of circulating microRNAs as potential bio-
markers for epilepsy. An initial study in a rat model of TLE [29], identified differences in
plasma levels of miR-21, miR-146 and miR-142 in different phases of the epileptogenic pro-
cess. More recently, Wang and collaborators [12] published the first report identifying differ-
ences in expression levels of circulating microRNAs in serum in a mix group of patients with
partial and generalized epilepsy. Subsequently, the same authors [13], studying a clinically
Circulating hsa-miR-134 in MTLE
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heterogeneous group of drug-resistant and drug-responsive patients with idiopathic and cryp-
togenic epilepsy found abnormal expression levels of hsa-miR-301a as a good candidate to
discriminate these two groups. Because of the remarkable heterogeneity in terms of aetiology
and underlying mechanisms in different forms of epilepsy, we designed the present study to
include well defined epilepsy syndromes aiming to avoid the confounding factors which could
hinder the identification of reliable biomarkers in epilepsy [30].
It was recently shown that circulating microRNAs can be deregulated by precedent seizures
[14], in order to investigate this issue we used a score of up to one seizure per month to define
two groups of patients and found no statistical difference regarding plasma levels of hsa-miR-
134 plasma, which further indicates that hsa-miR-134 plasma levels are indeed stable across a
number of potential confounding variables. We are also aware that AEDs may have an effect
on circulating microRNAs [31]. Unfortunately, our sample size is rather small due to the high
variability of antiepileptic drug treatments and daily drug dose. However, since we found no
difference in hsa-miR-134 plasma levels between AED-responsive and AED-resistant MTLE
patients, which have clear differences in AED daily doses as well as AED-regimen, we believe
this is an indication that hsa-miR-134 plasma levels may not suffer significant changes due to
the effect of different AEDs.
Although our results can be considered of marginal statistical significance, they indicate the
need for additional large studies, ideally including different patients with different types of
epilepsy syndromes, seizure frequency and AED-regimen. In addition, it is more realistic to
assume that no single biomarker will attain 100% sensitivity of specificity and that a combina-
tion of different biomarkers together with clinical information is more likely to be used in clin-
ical practice.
In conclusion, we showed that decreased expression of hsa-miR-134 could be a potential
and non-invasive biomarker to support the diagnosis of patients with MTLE. In addition, we
have presented evidence supporting our findings in two independent cohorts of patients with
MTLE. Therefore, we suggest that the determination of hsa-miR-134 plasma levels could rep-
resent a valuable tool to support the diagnosis of patients with MTLE in conjunction with clin-
ical, EEG, and imaging parameters, pending additional confirmatory studies.
Supporting information
S1 Table. MicroRNAs expression and clinical findings in patients with FCD, MTLE and
control individuals enrolled in discovery and validation phases.
(XLSX)
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